Interesting facts
Interesting Facts About [(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-6a,8,9,10-tetrahydro-6H-indolo[4,3-fg]quinolin-9-yl]methyl 5-bromopyridine-3-carboxylate
This compound belongs to a fascinating category of chemicals known for their complex structures and significant biological activities. Here are some compelling facts:
- Structural Complexity: The compound's intricate molecular architecture is highlighted by its indoloquinoline backbone, which is a feature associated with various pharmacological agents.
- Biological Activity: Compounds with similar structures are often investigated for their ability to interact with biological systems. They may exhibit anti-cancer properties or serve as potential neuroprotective agents.
- Synthetic Pathways: The synthesis of this compound showcases advanced methodologies in organic chemistry, often involving multi-step reactions that demonstrate a chemist's ability to navigate complex reaction sequences.
- Substituent Influence: The presence of a 5-bromopyridine-3-carboxylate moiety adds an electrophilic character to the compound, potentially influencing its reactivity and interaction with biological targets.
- Research Interest: Given the unique combination of features, this compound is likely to be the subject of ongoing research within medicinal chemistry, particularly in the search for new therapeutic agents.
As noted in the field, “Chemistry is the art of transformation, and synthesizing such compound is a true testament to the creativity and innovation of chemists.” The exploration of compounds like this one expands our understanding of chemical interactions and paves the way for novel drug discoveries.
Synonyms
nicergoline
27848-84-6
Nimergoline
Sermion
ergobel
Nicergolina
Nicotergoline
cergodum
duracebrol
nicergolent
Nicergolinum
Vasospan
Circo-Maren
Dilasenil
Ergotop
Nilogrin
Memoq
DTXSID7045607
JCV8365FWN
10-Methoxy-1,6-dimethylergoline-8beta-methanol 5-bromonicotinate
NSC-150531
FI-6714
Circo Maren
DTXCID5025607
Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, 5-bromo-3-pyridinecarboxylate (ester), (8beta)-
[(2S,4R,7R)-2-methoxy-6,11-dimethyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]methyl 5-bromopyridine-3-carboxylate
Nicergolin TEVA
Nicergolin ratiopharm
Von Ct, Nicergolin
Nicergolin neuraxpharm
((8R,10S)-10-Methoxy-1,6-dimethylergolin-8-yl)methyl 5-bromopyridine-3-carboxylate
[(8R,10S)-10-Methoxy-1,6-dimethylergolin-8-yl]methyl 5-Bromopyridine-3-carboxylate
((2S,4R,7R)-2-methoxy-6,11-dimethyl-6,11-diazatetracyclo(7.6.1.0^(2,7).0^(12,16))hexadeca-1(16),9,12,14-tetraen-4-yl)methyl 5-bromopyridine-3-carboxylate
RefChem:853815
C04AE02
248-694-6
MFCD00869626
Nimergoline base
C24H26BrN3O3
Sermion (TN)
10-Methoxy-1,6-dimethylergoline-8beta-methanol 5-bromonicotinate (ester)
Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-,5-bromo-3-pyridinecarboxylate (ester), (8b)-
CHEBI:31902
Nicergolin [German]
Nicergolina [DCIT]
RP 19651
NCGC00017259-04
Nicergolinum [INN-Latin]
Nicergolin
5-Bromonicotinic acid 10-methoxy-1,6-dimethylergoline-8-methyl ester
((6AR,9R,10AS)-10A-METHOXY-4,7-DIMETHYL-4,6,6A,7,8,9,10,10A-OCTAHYDROINDOLO[4,3-FG]QUINOLIN-9-YL)METHYL 5-BROMONICOTINATE
[(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-6a,8,9,10-tetrahydro-6H-indolo[4,3-fg]quinolin-9-yl]methyl 5-bromopyridine-3-carboxylate
[(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-6a,8,9,10-tetrahydro-6H-indolo[4,3-fg]quinoline-9-yl]methyl 5-bromopyridine-3-carboxylate
CAS-27848-84-6
FI 6714
10-Methoxy-1,6-dimethyl-ergolin-8-beta-methanol-(5-bromnicotinat)
SR-01000597616
MNE
EINECS 248-694-6
UNII-JCV8365FWN
NSC 150531
BRN 4828393
1-Methyl-lumilysergol 8-(5-bromonicotinate) 10-methyl ether
(+)-10-Methoxy-1,6-dimethylergoline-8-beta-methanol 5-bromonicotinate
Nicergoline [USAN:INN:BAN:JAN]
10-Methoxy-1,6-dimethyl-ergolin-8-beta-methanol-(5-bromnicotinat) [German]
8-beta-((5-Bromonicotinoyloxy)methyl)-1,6-dimethyl-10-alpha-methoxyergoline
10-Methoxy-1,6-dimethylergoline-8-methanol 5-bromo-3-pyrindinecarboxylate (ester)
Ergoline-8-beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromo-3-pyridinecarboxylate (ester)
Nicergoline (Standard)
Spectrum_001370
NICERGOLINE [MI]
Prestwick0_000147
Prestwick1_000147
Prestwick2_000147
Prestwick3_000147
Spectrum2_001414
Spectrum3_001933
Spectrum4_000440
Spectrum5_001352
NICERGOLINE [INN]
NICERGOLINE [JAN]
NICERGOLINE [USAN]
Ergoline-8-beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester)
Ergoline-8beta-methanol, 10-methoxy-1,6-dimethyl-, 5-bromonicotinate (ester)
Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, (8beta)-, 5-bromo-3-pyridinecarboxylate (ester)
NICERGOLINE [MART.]
SCHEMBL22964
BSPBio_000254
BSPBio_003533
KBioGR_000800
KBioSS_001850
NICERGOLINE [WHO-DD]
DivK1c_000124
SPECTRUM1501133
SPBio_001488
SPBio_002193
BPBio1_000280
orb1309661
CHEMBL1372950
Nicergoline - Bio-X trade mark
SCHEMBL29561276
HMS500G06
HY-B0702R
KBio1_000124
KBio2_001850
KBio2_004418
KBio2_006986
KBio3_002787
Nicergoline (JP17/USAN/INN)
Nicergoline for system suitability
NINDS_000124
HMS1568M16
HMS1923O09
HMS2089I03
HMS2092F07
HMS2095M16
HMS3712M16
HMS3886C03
NICERGOLINE [EP MONOGRAPH]
Nicergoline for peak identification
Pharmakon1600-01501133
EX-A4135
HY-B0702
Tox21_110810
CCG-39032
NSC757853
s4797
AKOS005067888
AKOS015969107
Tox21_110810_1
DB00699
FB01518
Nicergoline 1.0 mg/ml in Acetonitrile
NSC-757853
IDI1_000124
QTL1_000060
NCGC00017259-03
NCGC00017259-05
NCGC00017259-07
NCGC00024678-02
NCGC00024678-03
AS-12239
BN166697
ST055762
SY059965
SBI-0051652.P002
N0904
D01290
T72213
AB00052214-04
AB00052214_05
EN300-7361926
848N846
SR-05000001751
Nicergoline, analytical standard, for drug analysis
Q2623398
SR-01000597616-1
SR-01000597616-2
SR-05000001751-1
BRD-K76810206-001-05-7
BRD-K76810206-001-06-5
BRD-K76810206-001-07-3
BRD-K76810206-001-08-1
Nicergoline, European Pharmacopoeia (EP) Reference Standard
(8beta)-10-methoxy-1,6-dimethylergoline-8-methanol 5-bromo-3-pyridinecarboxylate (ester)
Nicergoline for peak identification, European Pharmacopoeia (EP) Reference Standard
Nicergoline for system suitability, European Pharmacopoeia (EP) Reference Standard
((6AR,9R,10AS)-10A-METHOXY-4,7-DIMETHYL-4,6,6A,7,8,9,10,10A-OCTAHYDROINDOLO[4,3-FG]QUINOLIN-9-YL)METHYL5-BROMONICOTINATE
[(2S,4R,7R)-2-methoxy-6,11-dimethyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(15),9,12(16),13-tetraen-4-yl]methyl 5-bromopyridine-3-carboxylate
5-Bromonicotinic acid 10-methoxy-1,6-dimethylergoline-8-methyl ester;[(8R,10S)-10-Methoxy-1,6-dimethylergolin-8-yl]methyl 5-bromopyr idine-3-carboxylate
5-Bromonicotinic acid 10-methoxy-1,6-dimethylergoline-8-methyl ester;[(8R,10S)-10-Methoxy-1,6-dimethylergolin-8-yl]methyl 5-bromopyr idine-3-carboxylate
5-Bromopyridine-3-carboxylic Acid [(8R,10S)-10-Methoxy-1,6-dimethylergolin-8-yl]methyl Ester
ERGOLINE-8-METHANOL, 10-METHOXY-1,6-DIMETHYL-, (8.BETA.)-, 5-BROMO-3-PYRIDINECARBOXYLATE (ESTER)
Solubility of [(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-6a,8,9,10-tetrahydro-6H-indolo[4,3-fg]quinolin-9-yl]methyl 5-bromopyridine-3-carboxylate
The solubility of this complex compound can be influenced by several factors, including its molecular structure and the nature of the substituents present. Here are some key points to consider regarding its solubility:
Overall, while the structure suggests potential solubility in polar organic solvents, factors such as solute-solvent interactions and temperature must be carefully examined for a complete understanding of its solubility behavior. As noted, "the solubility of a compound is a pivotal aspect of its chemical behavior" which influences its applications in various fields.